Abstract
Background and Aim We have evaluated procalcitonin (PCT) as a diagnostic marker for bacterial gastroenteritis (GE) and as a disease activity marker in inflammatory bowel disease (IBD) patients. Methods This was a prospective single-center study performed over a 1-year period. Venous blood samples were drawn from hospitalized patients with acute GE and tested for PCT, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and total white cell count (TWC); stools from the same patients were tested for standard pathogens. Venous blood samples from patients with IBD were tested for PCT, CRP, ESR, and platelet count. The PCT level was measured using an immunofluorescent assay, with normal being defined as <0.5 ng/ml. Results The GE arm of study consisted of 81 patients, 18.5% of whom were diagnosed with bacterial GE. The PCT and CRP levels were good diagnostic markers of bacterial GE, with an area under the curve (AUC) of 0.727 [95% confidence interval (CI) 0.580–0.874] and 0.786 (95% CI 0.627–0.946), respectively. An elevated PCT ≥0.5 ng/ml was associated with a 13-fold increased risk of renal impairment. The IBD arm of study consisted of 72 IBD patients. The PCT levels were not significantly different between active and inactive IBD in this patient cohort. Conclusion Our results indicate that PCT and CRP are comparably good diagnostic markers of bacterial GE but that PCT is not useful as in monitoring disease activity in patients with IBD.
Similar content being viewed by others
References
World Health Organisation (1996) The World Health report 1996: fighting disease, fostering development. Report of the Director-General. World Health Organisation, Geneva
Kosek M, Bern C, Guerrant RL (2003) The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000. Bull World Health Organ 81:197–204
Pavia AT, Shipman LD, Wells LG et al (1990) Epidemiologic evidence that prior antimicrobial exposure decreases resistance to infection by antimicrobial-sensitive Salmonella. J Infect Dis 161:255–260
Guerrant RL, Gilder TV, Steiner TS et al (2001) Practice guidelines for the management of infectious diarrhea. Clin Infect Dis 32:331–351
Koplan JP, Fineberg HV, Ferraro MJ, Rosenberg M (1980) Value of stool cultures. Lancet 2:413–416
Guerrant R, Shields D, Thorson S, Schorling J, Groschel D (1985) Evaluation and diagnosis of acute infectious diarrhea. Am J Med 78:91–98
Slutsker L, Ries AA, Greene KD, Wells JG, Hutwagner L, Griffin PM (1997) Escherichia coli O157:H7 diarrhea in the United States: clinical and epidemiologic features. Ann Intern Med 126:505–513
Cohen ML, Tauxe RV (1986) Drug-resistant Salmonella in the United States: an epidemiologic perspective. Science 234:964–969
Ouyang Q, Tandon R, Goh KL, Ooi CJ, Ogata H, Fiocchi C (2005) The emergence of inflammatory bowel disease in the Asian Pacific region. Curr Opin Gastroenterol 21:408–413
Bruining DH, Loftus EV (2006) Evolving diagnostic strategies for inflammatory bowel disease. Curr Gastroenterol Rep 8:478–485
Desai D, Faubion WA, Sandborn WJ (2007) Review article: biological activity markers in inflammatory bowel disease. Aliment Pharmacol Ther 25:247–255
Solem CA, Loftus EV, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ (2005) Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 11:707–712
Boiliviant M, Leoni M, Tariciotti D et al (1988) The clinical significance of serum C reactive protein in Crohn’s disease: result of a prospective longitudinal study. J Clin Gastroenterol 10:401–405
Sandborn WJ, Feagan BG, Radford-Smith G et al (2004) CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn’s disease: a randomised, double blind, placebo controlled trial. Gut 53:1485–1493
Vermeire S, Van-Assche G, Rutgeerts P (2006) Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 55:426–431
Moullec JML, Jullienne A, Chenais J et al (1984) The complete sequence of human preprocalcitonin. FEBS Lett 167:93–97
Whicher J, Bienvenu J, Monneret G (2001) Procalcitonin as an acute phase marker. Ann Clin Biochem 38:483–493
Enguix A, Rey C, Concha A, Medina A, Coto D, Dieguez MA (2001) Comparison of procalcitonin with C-reactive protein and serum amyloid for the early diagnosis of bacterial sepsis in critically ill neonates and children. Intensive Care Med 27:211–215
Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J (2004) Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 39:206–217
Rau B, Steinbach G, Gansauge F, Mayer JM, Grunert A, Beger HG (1997) The potential role of procalcitonin and interleukin 8 in the prediction of infected necrosis in acute pancreatitis. Gut 41:832–840
Brunkhorst FM, Eberhard OK, Brunkhorst R (1999) Discrimination of infectious and noninfectious causes of early acute respiratory distress syndrome by procalcitonin. Crit Care Med 27:2172–2176
Kuse ER, Langefeld I, Jaeger K, Kulpmann WR (2000) Procalcitonin in fever of unknown origin after liver transplantation: a variable to differentiate acute rejection from infection. Crit Care Med 28:555–559
Moosig F, Csernok E, Reinhold-Keller E, Schmitt W, Gross WL (1998) Elevated procalcitonin levels in active Wegener’s granulomatosis. J Rheumatol 25:1531–1533
Herrlinger KR, Dittman R, Weitz G et al (2004) Serum procalcitonin differentiates inflammatory bowel disease and self-limited colitis. Inflamm Bowel Dis 10:229–233
Baqui A, Black R, Yunus M et al (1991) Methodological issues in diarrhoeal diseases epidemiology: Definition of diarrhoeal episodes. Int J Epidemiol 20:1057–1063
RC RB, Balk R, FB FC et al (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101:1644–1655
Podolsky K (1991) Inflammatory bowel disease(1). N Engl J Med 325:928–937
Lennard-Jones J (1989) Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 24:2–6
Podolsky DK (1991) Inflammatory bowel disease (1) [see comment]. N Eng J Med 325:928–937
Harvey RF, Bradshaw JM (1980) A simple index of Crohn’s-disease activity. Lancet 1: 514
Truelove SC, Witts LT (1955) Cortisone in ulcerative colitis: final report on a therapeutic trial. Br Med J 2:1041–1048
Levine DS, Riff DS, Pruitt R et al (2002) A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. Am J Gastroenterol 97:1398–1407
Korczowski B, Szybist W (2004) Serum procalcitonin and C-reactive protein in children with diarrhoea of various aetiologies. Acta Paediatr 93:169–173
Novotny A, Emmanuel K, Matevossian E et al (2007) Use of procalcitonin for early prediction of lethal outcome of postoperative sepsis. Am J Surg 194:35–39
Muller B, Harbarth S, Stolz D et al (2007) Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis 7:10
Powell DW (1991) Approach to the patient with diarrhea. In: Yamada T, Alpers DH, Owyong C et al (eds) Textbook of gastroenterology. JB Lippincott, Philadelphia,pp 732–769
Gore JI, Surawicz C (2003) Severe acute diarrhea. Gastroenterol Clin North Am 32:1249–1267
Vermeire S, Van Assche G, Rutgeerts P (2004) C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 10:661–665
Delevaux I, Andre M, Colombier M et al (2003) Can procalcitonin measurement help in differentiating between bacterial infection and other kinds of inflammatory processes? Ann Rheum Dis 62:337–340
Acknowledgements
This study was funded by the Singhealth Project-Based Research Foundation Grant. PCT kits were provided free, courtesy of Dyamed Biotech Pte Ltd. We would like to thank our Head of Department, A/P Chow Wan Cheng, for her support of this investigator-initiated clinical research. We also express our appreciation to Dr. Ang Teck-Kee and Dr. Wee Jeremy for assisting with patient recruitment.
Contribution to Paper
Study concept and design (KTT), clinical studies (KTT, WYN, EJ, CJO), data acquisition (KTT), data analysis and interpretation (KTT, LKL, CJO, ESYC), statistical analysis (ESYC), manuscript preparation (KTT), manuscript revision, editing, final approval (all authors).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Thia, K.TJ., Chan, E.SY., Ling, KL. et al. Role of Procalcitonin in Infectious Gastroenteritis and Inflammatory Bowel Disease. Dig Dis Sci 53, 2960–2968 (2008). https://doi.org/10.1007/s10620-008-0254-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-008-0254-6